Cibus, Inc. (CBUS) vs Pyxis Oncology, Inc. (PYXS)

A side-by-side comparison of Cibus, Inc. and Pyxis Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CBUS vs PYXS

growth of $100 · dividends reinvested · last 5y
CBUS -98.9% (-59.5%/yr)PYXS -83.0% (-29.9%/yr)PYXS compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020222023202420252026$1$17
CBUS PYXS

CBUS vs PYXS: by the numbers

  • •PYXS is the larger company ($128M vs $120M market cap).
  • •Both run net losses; PYXS's is the smaller (-803.83% vs -2258.89% net margin).

Metrics side by side

Valuation

MetricCBUSPYXS
P/S ratio27.5711.59
P/B ratio8.1011.19

Profitability

MetricCBUSPYXS
Gross margin-62.76%82.77%
Operating margin-1853.92%-609.18%
Net margin-2258.89%-803.83%
ROE-663.38%-775.59%
ROIC-17.99%-314.66%

Growth (annualized)

MetricCBUSPYXS
Revenue CAGR (5Y)-34.28%N/A
Total return CAGR (5Y)-59.70%N/A

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.